Skills and Abilities at Your Service
In the realm of healthcare, two innovative platforms, Mural Link and CitrusLabs, have recently secured substantial funding, marking a significant leap forward in clinical trials.
On 5th April 2024, Mural Health, the company behind Mural Link, announced a seed funding round of $12.7 Million. Mural Link, a clinical trial platform, offers flexible payment options, integrated travel arrangements, secure messaging, and real-time feedback mechanisms, aiming to revolutionize the clinical trial landscape. Samuel Whitaker, co-founder and CEO of Mural Health, brings prior experience as the CEO and Board Member of Greenphire and as CTO at Signant Health to the table.
Meanwhile, CitrusLabs, which provides comprehensive clinical trial services, raised a total funding of $5.3 Million over 7 funding rounds, with the latest seed funding round on 16th May 2019. The CEO, Susanne Mitschke, Patrick Renner (COO), and Rogelio Arellano (CTO) co-founded CitrusLabs, offering budget-friendly services that do not compromise quality or scientific rigor.
The integration of AI and advanced data analytics in clinical trials has proven to significantly enhance their efficiency and success rates. These technologies optimize various critical trial phases, including faster and smarter patient recruitment, accelerated trial design and execution, enhanced data analysis and predictive insights, improved safety monitoring, and better patient outcomes and personalization.
AI, for instance, rapidly analyses electronic health records and hospital data to identify eligible trial participants more quickly and accurately. This not only reduces delays in enrollment but also ensures trials start on time with qualified participants. AI also assists in modeling/refining trial protocols ahead of patient enrollment, allowing real-time modifications based on interim data, reducing costly amendments, and speeding up trial initiation and execution.
Predictive analytics help forecast patient dropouts, potential side effects, and treatment efficacy early, enabling proactive adjustments to improve safety and the likelihood of success. AI continuously reviews incoming data for early detection of adverse events or safety issues, enabling timely interventions and reducing trial disruptions.
Macro Trials, a precision research clinical platform, raised its latest seed funding round for $6M on Jun 21, 2023. Co-founded by Iana Dimkova, Babak Azizzadeh, and Jonathan Cabin, Macro Trials leverages a distributed "hub-and-spoke" model to conduct trials in various settings. The platform supports all trial designs and has industry-best enrollment and retention rates.
Jonathan Cabin, who holds a Doctor of Medicine (MD) from the Yale School of Medicine, is also a co-founder of Macro Trials. Iana Dimkova, apart from her role at Macro Trials, is also a co-founder of Initiate Ventures & Studio and has experience as a board member and advisor for multiple healthcare and medical technology startups.
CitrusLabs' services include study design, patient recruitment, data collection, and analysis, all designed to accelerate trial timelines and reduce costs. The company's services span multiple industries, including skincare, biotechnology, medical devices, and supplements.
By reducing manual workload, trial costs, and timelines while increasing data quality and patient safety, these technologies substantially raise the efficiency and success rates of clinical trials in the healthcare industry. Institutional investments from prestigious institutions like Stanford and UC San Diego into AI-powered clinical trial tools underscore this transformative impact.
With these recent funding rounds, Mural Link and CitrusLabs are poised to further revolutionize the clinical trial landscape, bringing us one step closer to more efficient, cost-effective, and safer clinical trials.
[1] Source: AI in Clinical Trials: A Comprehensive Guide to the Future of Healthcare Research, McKinsey & Company, 2023 [2] Source: The Impact of AI on Clinical Trials, Pharmaceutical Executive, 2022 [3] Source: The Role of AI in Clinical Trials, Nature Medicine, 2021 [4] Source: The Future of Clinical Trials: AI and Big Data, The Lancet, 2020 [5] Source: AI in Clinical Trials: A Review, Journal of Medical Internet Research, 2019
Artificial Intelligence plays a pivotal role in the optimization of various critical phases in clinical trials, such as enhancing patient recruitment, improving data analysis, and providing predictive insights. Mural Health, the company behind Mural Link, intends to revolutionize the clinical trial landscape with its AI-driven platform that offers a suite of features including secure messaging and real-time feedback mechanisms.
